CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Market
0.0%
Details
- Resolved Date
- 8/1/24
- Study Completion
- 3/31/26
- Company
- TaiRx, Inc.
- Ticker
- 6580.TWO
- Type
- Trial Status
- Recruiting
- Trial Size
- 95
- Volume
- $0
- NCT
- NCT05257590
- Drug Description
- CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
An exact-trial conference abstract for NCT05257590 reports the combo “demonstrated clinical activity,” had a favorable safety profile, and “support[s] further development,” which is clear positive framing for this study. ClinicalTrials.gov still shows the study as recruiting, so this appears to be an interim positive public readout.
Sources
Web Searchs3.amazonaws.com8/1/24
BT24 Abstracts PDF: CVM-1118 with nivolumab in unresectable advanced HCC—A phase IIa study
For NCT05257590, the abstract concludes CVM-1118+nivolumab “demonstrated clinical activity” in advanced HCC and that the data “support further development” of the combination.
View source
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov: NCT05257590 study details
ClinicalTrials.gov lists NCT05257590 as a Phase 2 study of CVM-1118 plus nivolumab in unresectable advanced hepatocellular carcinoma and shows the trial as recruiting.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
